Neuropeptides · Neuropeptide receptor ligand · NEUP-111
Diazepam-Binding Inhibitor Fragment, human
- Drug class
- Neuropeptide receptor ligand
- Status
- Research use only
- Catalog code
- NEUP-111
- Also known as
- NEUP-111
- Reviewed
- 2026-06-01 · Kindr Health Clinical Team
What Diazepam-Binding Inhibitor Fragment, human is studied for
- GPCR receptor-binding and functional profiling
- Behavioral pharmacology (rodent models)
- Pain, mood, and anxiety-circuit research
- Neuroendocrine feedback studies
Mechanism of action
Diazepam-Binding Inhibitor Fragment, human sits within the Neuropeptides research class (CPC reference NEUP-111). Neuropeptides bind GPCRs expressed on central and peripheral neurons — modulating cAMP, calcium, and β-arrestin signaling to shape neurotransmission, network excitability, and behavior. Investigators typically incorporate Diazepam-Binding Inhibitor Fragment, human as a reference standard, tool ligand, or substrate in the assay contexts listed above. Radioligand binding, cAMP HTRF, calcium mobilization, and in vivo behavior assays.
Frequently asked questions
What is Diazepam-Binding Inhibitor Fragment, human?
Diazepam-Binding Inhibitor Fragment, human (CPC catalog code NEUP-111) is a synthetic neuropeptide receptor ligand in the neuropeptides category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.
What is Diazepam-Binding Inhibitor Fragment, human studied for?
Published and internal research programs use Diazepam-Binding Inhibitor Fragment, human as a reference standard in neuropeptides workflows — for example, gpcr receptor-binding and functional profiling and behavioral pharmacology (rodent models). Human clinical evidence is not established.
Is Diazepam-Binding Inhibitor Fragment, human FDA-approved for human use?
No. Diazepam-Binding Inhibitor Fragment, human is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.
How is Diazepam-Binding Inhibitor Fragment, human typically used in the lab?
In a neuropeptides workflow, Diazepam-Binding Inhibitor Fragment, human is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. Radioligand binding, cAMP HTRF, calcium mobilization, and in vivo behavior assays.
How should Diazepam-Binding Inhibitor Fragment, human be stored?
Store lyophilized at −20 °C. Reconstitute in sterile 0.1% BSA/PBS to reduce adsorption. Follow your institution's standard operating procedures for handling synthetic peptides.
Where does the Diazepam-Binding Inhibitor Fragment, human product page point to?
This kindr reference page mirrors CPC Scientific's catalog metadata for NEUP-111. The upstream reference sheet — including sequence, purity, MW, and application notes where published — is linked from the buy panel. All orders placed on kindr Peptides ship internationally under research-use terms only.
What quality specifications apply to Diazepam-Binding Inhibitor Fragment, human?
Research-grade peptides in the CPC catalog are synthesized by solid-phase peptide synthesis (SPPS), purified by preparative RP-HPLC, and characterized by analytical HPLC and mass spectrometry. Typical purity is ≥95%; certificate of analysis is available on request.
Related peptides in Neuropeptides
Continue across the Kindr entity graph
Related evidence, peptides, and clinical tools on the same topic.
- Is HRT safe?Journal
- When to start HRTJournal
- Menopause HRT serviceMedication
- Complete menopause guideJournal